IBDEI18E ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,20937,1,4,0)
 ;;=4^R63.2
 ;;^UTILITY(U,$J,358.3,20937,2)
 ;;=^5019540
 ;;^UTILITY(U,$J,358.3,20938,0)
 ;;=R63.3^^84^941^72
 ;;^UTILITY(U,$J,358.3,20938,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20938,1,3,0)
 ;;=3^Feeding Difficulties
 ;;^UTILITY(U,$J,358.3,20938,1,4,0)
 ;;=4^R63.3
 ;;^UTILITY(U,$J,358.3,20938,2)
 ;;=^5019541
 ;;^UTILITY(U,$J,358.3,20939,0)
 ;;=R63.4^^84^941^29
 ;;^UTILITY(U,$J,358.3,20939,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20939,1,3,0)
 ;;=3^Abnormal Weight Loss
 ;;^UTILITY(U,$J,358.3,20939,1,4,0)
 ;;=4^R63.4
 ;;^UTILITY(U,$J,358.3,20939,2)
 ;;=^5019542
 ;;^UTILITY(U,$J,358.3,20940,0)
 ;;=R63.5^^84^941^28
 ;;^UTILITY(U,$J,358.3,20940,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20940,1,3,0)
 ;;=3^Abnormal Weight Gain
 ;;^UTILITY(U,$J,358.3,20940,1,4,0)
 ;;=4^R63.5
 ;;^UTILITY(U,$J,358.3,20940,2)
 ;;=^5019543
 ;;^UTILITY(U,$J,358.3,20941,0)
 ;;=R64.^^84^941^46
 ;;^UTILITY(U,$J,358.3,20941,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20941,1,3,0)
 ;;=3^Cachexia
 ;;^UTILITY(U,$J,358.3,20941,1,4,0)
 ;;=4^R64.
 ;;^UTILITY(U,$J,358.3,20941,2)
 ;;=^17920
 ;;^UTILITY(U,$J,358.3,20942,0)
 ;;=R68.3^^84^941^51
 ;;^UTILITY(U,$J,358.3,20942,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20942,1,3,0)
 ;;=3^Clubbing of Fingers
 ;;^UTILITY(U,$J,358.3,20942,1,4,0)
 ;;=4^R68.3
 ;;^UTILITY(U,$J,358.3,20942,2)
 ;;=^5019553
 ;;^UTILITY(U,$J,358.3,20943,0)
 ;;=R73.01^^84^941^89
 ;;^UTILITY(U,$J,358.3,20943,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20943,1,3,0)
 ;;=3^Impaired Fasting Glucose
 ;;^UTILITY(U,$J,358.3,20943,1,4,0)
 ;;=4^R73.01
 ;;^UTILITY(U,$J,358.3,20943,2)
 ;;=^5019561
 ;;^UTILITY(U,$J,358.3,20944,0)
 ;;=R73.02^^84^941^90
 ;;^UTILITY(U,$J,358.3,20944,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20944,1,3,0)
 ;;=3^Impaired Glucose Tolerance (oral)
 ;;^UTILITY(U,$J,358.3,20944,1,4,0)
 ;;=4^R73.02
 ;;^UTILITY(U,$J,358.3,20944,2)
 ;;=^5019562
 ;;^UTILITY(U,$J,358.3,20945,0)
 ;;=R73.09^^84^941^15
 ;;^UTILITY(U,$J,358.3,20945,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20945,1,3,0)
 ;;=3^Abnormal Glucose NEC
 ;;^UTILITY(U,$J,358.3,20945,1,4,0)
 ;;=4^R73.09
 ;;^UTILITY(U,$J,358.3,20945,2)
 ;;=^5019563
 ;;^UTILITY(U,$J,358.3,20946,0)
 ;;=R73.9^^84^941^84
 ;;^UTILITY(U,$J,358.3,20946,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20946,1,3,0)
 ;;=3^Hyperglycemia,Unspec
 ;;^UTILITY(U,$J,358.3,20946,1,4,0)
 ;;=4^R73.9
 ;;^UTILITY(U,$J,358.3,20946,2)
 ;;=^5019564
 ;;^UTILITY(U,$J,358.3,20947,0)
 ;;=R76.11^^84^941^142
 ;;^UTILITY(U,$J,358.3,20947,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20947,1,3,0)
 ;;=3^Positive PPD
 ;;^UTILITY(U,$J,358.3,20947,1,4,0)
 ;;=4^R76.11
 ;;^UTILITY(U,$J,358.3,20947,2)
 ;;=^5019570
 ;;^UTILITY(U,$J,358.3,20948,0)
 ;;=R79.1^^84^941^3
 ;;^UTILITY(U,$J,358.3,20948,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20948,1,3,0)
 ;;=3^Abnormal Coagulation Profile
 ;;^UTILITY(U,$J,358.3,20948,1,4,0)
 ;;=4^R79.1
 ;;^UTILITY(U,$J,358.3,20948,2)
 ;;=^5019591
 ;;^UTILITY(U,$J,358.3,20949,0)
 ;;=R82.5^^84^941^69
 ;;^UTILITY(U,$J,358.3,20949,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20949,1,3,0)
 ;;=3^Elevated Urine Levels of Drug/Meds/Biol Subst
 ;;^UTILITY(U,$J,358.3,20949,1,4,0)
 ;;=4^R82.5
 ;;^UTILITY(U,$J,358.3,20949,2)
 ;;=^5019605
 ;;^UTILITY(U,$J,358.3,20950,0)
 ;;=R82.6^^84^941^26
 ;;^UTILITY(U,$J,358.3,20950,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20950,1,3,0)
 ;;=3^Abnormal Urine Levels of Subst of Nonmed Source
 ;;^UTILITY(U,$J,358.3,20950,1,4,0)
 ;;=4^R82.6
 ;;^UTILITY(U,$J,358.3,20950,2)
 ;;=^5019606
 ;;^UTILITY(U,$J,358.3,20951,0)
 ;;=R82.7^^84^941^27
